

Assessing IVD quality where regulations are not as prescriptive as needed

Braniff S-J and Best SJ
NRL, Melbourne, Australia

Outline

- Definitions
- The evaluation process
 - Review of manufacturer's data
 - Performance evaluation testing
- Resources

Definition: Verification

- Confirmation by examination and provision of objective evidence that specified requirements have been fulfilled (ISO 9000:2005)
- Process of demonstrating the performance criteria included in the method can be met by the facility prior to introducing them for routine use. (NATA Technical Note 17)

Definition: Validation

The process of proving that a procedure, process, system, equipment, or method works as expected and achieves the intended result. (CLSI)

Definition: Evaluation

- An investigation that measures the performance capabilities of an assay (CLSI).
- **at a point in time.**

The purpose of test kit evaluations

- Confirm that the test kit will perform satisfactorily according to its intended use.
- Minimise the risk of harm:
 - *Safety of blood products*
 - *Accurate clinical diagnoses and effective disease management*
- Provide comparative data for future evaluations

The purpose of test kit evaluations

- Estimate test kit performance under local conditions, using specimens representative of the local population.
- Evaluations focus on test kit performance.
 - Not on quality of manufacture.
- Provides independent evidence of test kit performance.

The evaluation process

- Two parts:
 - Review of manufacturer's evidence
 - Dossier or “desktop” review
 - Laboratory performance evaluation
- Either one or both

Review manufacturer's evidence

- Manufacturers apply to a country's NRA for test kit registration
- A dossier of evidence is submitted, this will include:
 - Test kit Instructions for Use (IFU)
 - Performance data
 - Analytical (pre-clinical)
 - Clinical
 - Stability
- Review by NRA / evaluating laboratory

The Instructions for Use

- Examine the intended use statement within the test kit IFU
 - What is the level of risk?
 - e.g. “Screening test” vs. “Genotyping test”
- Level of Risk informs how the evaluation is performed
- Examine the summary of performance characteristics

Example: Intended use of a NAT screening test kit

The XXXXXXXXXX Assay is a **qualitative** *in vitro* nucleic acid amplification test for the detection of human immunodeficiency virus type 1 and human immunodeficiency virus type 2 (HIV) RNA, hepatitis C virus (HCV) RNA, and/or hepatitis B virus (HBV) DNA in **plasma and serum specimens** from human **donors**, **tested individually or in pools**. It is also intended for use in testing plasma and serum to **screen** organ and tissue **donors**, including **cadaveric** (non-heart-beating) donors.

It is not intended for use on samples of cord blood.

This assay is not intended for use as an aid in diagnosis.

Manufacturer's performance data

- Does the data presented support the test kit's intended use?
- Have sufficient tests been performed?
 - European Union "Common Technical Specifications (CTS) for In Vitro Diagnostic Medical Devices" are a useful guide
- Do the samples tested represent the local population?
- Are the data scientifically sound?
- Is more evidence required – does the evidence presented require clarification?

Performance evaluation process



- Develop Performance Evaluations Process SOP



Consistent approach

Performance evaluation process

Protocol

- Develop a testing protocol that defines:
 - Aim
 - Parameters for investigation
 - Resources required / available
 - *Human, equipment, reagents, specimen panels*
 - Statistical analyses & acceptance criteria
 - Timeframe
 - Safety requirements
- Make use of testing regulations & guidelines e.g.
 - **NPAAC**; **NATA**: Technical note 17; **CLSI**


Performance evaluation process

Specimens

● Performance characteristics

- Sensitivity → positive panels
→ seroconversion panels?
 - Specificity → blood donor samples
→ hospitalised patients?
 - Pools?
 - Ability to detect different subtypes
 - Precision
 - Lot-to-lot variation
- ### ● How many samples is enough?
- Statistical confidence

95% Confidence Interval



Performance evaluation process



- Follow the protocol
 - Data for the validation should be generated from the final protocol
- Keep accurate and complete records
 - A third party needs to be able to analyse and interpret the data

Performance evaluation process

Report

- Scientific format
- Communicate data effectively
- Include all relevant findings
 - Report confidence intervals
 - Summary tables
 - Appendix for complete data tables
- Correct labelling → tables and graphs
- Consistency of specimen numbers
- Peer review before submission

Some resources

- **Clinical Laboratory Standards Institute (CLSI)**
(clsi.org)
- **NATA:** Technical note 17 (www.nata.com.au)
- **NPAAC:** Requirements for the development and use of in-house and in vitro diagnostic devices
(www.health.gov.au/npaac)

Summary

- A test kit evaluation programme seeks to ensure that:
 - only *high quality* test kits are supplied
 - risks understood and minimised
- This ensures:
 - the safety of blood transfusions,
 - the accuracy of clinical diagnoses, and
 - effective donor / disease management
- Use available resources